Treatment of laryngeal contact ulcers and granulomas: a 12-year retrospective analysis.
Multiple etiological factors including gastroesophageal reflux, hyperfunctional voice use, and endotracheal intubation have been implicated in the development of posterior laryngeal ulcers and granulomas. The optimal approach to treatment of these lesions remains controversial. The mainstay of treatment at Vancouver General Hospital has been aggressive medical management of gastroesophageal reflux, with complimentary voice therapy offered to patients suspected of having significant hyperfunctional phonation. The authors reserve Botulinum toxin injection or surgical excision for patients who fail initial therapy. They conducted a retrospective analysis of their voice clinic records from 1985-1997 to examine the efficacy of this approach. They identified 76 patients with the diagnosis of contact ulcer or granuloma. Fifty-two patients had follow-up data available for review. Ninety-four percent of patients were treated nonsurgically: 35 patients were treated solely by dietary and medical therapy to control gastroesophageal reflux, 10 patients were treated by a combination of medical gastroesophageal reflux control and voice therapy, 3 patients had Botox injections, 2 patients had surgical excision of granuloma, 1 patient had a Kenalog injection, and 1 patient underwent laparoscopic fundoplication. Overall, 77% of patients had complete resolution, whereas 11% had partial resolution and another 11% had no significant improvement. The data supports control of gastroesophageal reflux as a central component in treatment of posterior laryngeal ulcers and granulomas.
Emami
A J
AJ
Department of Surgery, University of British Columbia, Vancouver, Canada.
Morrison
M
M
Rammage
L
L
Bosch
D
D
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005260:Female; D006099:Granuloma / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D007818:Laryngeal Diseases / Q000188:drug therapy* / Q000601:surgery*; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D009853:Omeprazole / Q000627:therapeutic use*; D012189:Retrospective Studies; D014456:Ulcer / Q000188:drug therapy* / Q000601:surgery*
D000897:Anti-Ulcer Agents; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; D009853:Omeprazole